Abstract:Background & aims: Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder causing pulmonary and liver disease. The PiZ mutation in AAT (SERPINA1) results in mis-folded AAT protein (Z-AAT) accumulating in hepatocytes, leading to fibrosis and cirrhosis. RNAi-based therapeutics silencing production of hepatic Z-AAT might benefit patients with AATD-associated liver disease. This study evaluated an RNAi therapeutic to silence production of AAT. Methods: Part A of this double-blind first-in-human study randomized 54 healthy volunteers (HVs) into single dose cohorts (two placebo: four active), receiving escalating doses of the investigational agent ARC-AAT from 0.38 to 8.0 mg/kg or placebo. Part B randomized 11 patients with PiZZ (homozygous for Z-AAT) genotype AATD, who received up to 4.0 mg/kg of ARC-AAT or placebo. Patients with baseline FibroScan® >11 kPa or forced expiratory volume in one second (FEV1) <60% were excluded. Assessments included safety, pharmacokinetics, and change in serum AAT concentrations. Results: A total of 36 HVs received ARC-AAT and 18 received placebo (part A). Seven PiZZ individuals received ARC-AAT and four received placebo (part B). A dose response in serum AAT reduction was observed at doses ≥4 mg/kg with similar relative reductions in PiZZ patients and HVs at 4 mg/kg and a maximum reduction of 76.1% (HVs) vs. 78.8% (PiZZ) at this dose. The time it took for serum AAT to return to baseline was similar for HV and PiZZ. There were no notable differences between HV and PiZZ safety parameters. The study was terminated early because of toxicity findings related to the delivery vehicle (ARC-EX1) seen in a non-human primate study. Conclusion: PiZZ patients and HVs responded similarly to ARC-AAT. Deep and durable knockdown of hepatic AAT production based on observed reduction in serum AAT concentrations was demonstrated. Lay summary: Accumulation of abnormal proteins in the livers of patients with alpha-1 antitrypsin deficiency may lead to decreased liver function and potentially liver failure. Therapeutics targeting the production of these abnormal proteins may be used to prevent or treat liver disease in patients with alpha-1 antitrypsin deficiency. Clinical trial registration number: NCT02363946.

Lack of Effect of Oral 4‐Phenylbutyrate on Serum Alpha‐1‐Antitrypsin in Patients with α‐1‐Antitrypsin Deficiency: A Preliminary Study

Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency

Advances in Alpha-1-Antitrypsin Deficiency Liver Disease

Berberine potentiates liver inflammation and fibrosis in the PI*Z hAAT transgenic murine model

Liver disease with unknown etiology – have you ruled out alpha-1 antitrypsin deficiency?

Emerging Concepts and Human Trials in Alpha-1-Antitrypsin Deficiency Liver Disease

Increased Intestinal Clearance of $aP 1 ‐Antitrypsin in Patients with $aP 1 ‐Antitrypsin Deficiency

Cleaning up alpha-1 antitrypsin deficiency related liver disease

Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients

Effect of Aerosolized Α_1-Antitrypsin on Pseudomonas Aeruginosa Pneumonia in Rats

Fibrosis, biomarkers and liver biopsy in AAT deficiency and relation to liver Z protein polymer accumulation

Research progress ofα1-antitrypsin deficiency of mutant Z

Liver Characterization of a Cohort of Alpha-1 Antitrypsin Deficiency Patients with and without Lung Disease

Lung Inflammation in alpha-1-antitrypsin deficient individuals with normal lung function

Ferret models of alpha-1 antitrypsin deficiency develop lung and liver disease

KF4 anti-CELA1 Antibody and Purified α1-Antitrypsin Have Similar but Not Additive Efficacy in Preventing Emphysema in Murine α1-Antitrypsin Deficiency

Alpha-1 antitrypsin deficiency impairs lung antibacterial immunity in mice

Review article: New developments in biomarkers and clinical drug development in alpha‐1 antitrypsin deficiency‐related liver disease

Evaluation of cytosine base editing and adenine base editing as a potential treatment for alpha-1 antitrypsin deficiency

Immunological and homeostatic pathways of alpha -1 antitrypsin: a new therapeutic potential

Beneficial effects of alpha-1 antitrypsin therapy in a mouse model of colitis-associated colon cancer